# Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer

> **NCT03153280** · PHASE1 · TERMINATED · sponsor: **Cancer Trials Ireland** · enrollment: 2 (actual)

## Conditions studied

- Colorectal Neoplasms
- Stomach Neoplasm
- Esophageal Neoplasms

## Interventions

- **DRUG:** Lithium
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03153280
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-13
- **Primary completion:** 2023-09-07
- **Final completion:** 2023-09-07
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Poor accrual and the field has moved on.
- **Last updated:** 2025-07-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03153280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03153280, "Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03153280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*